MARKET WIREYahoo Finance UK • 6h ago
TuHURA Biosciences, Inc. (HURA) Seasonal returns chartYahoo Finance UK report covering TuHURA Biosciences Inc. (HURA) market action, institutional positioning, and fundamental catalysts.
Why HURA Stock dropped -6.31% Today — RQD Quant Desk Flash
$1.93 -6.31% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $1.90
TuHURA Biosciences Inc. (HURA) carries a Roarable Rating of D- (Sell) with 40/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D- • RED ALERT
Cap $131.3M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on HURA Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is HURA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, TuHURA Biosciences Inc. (NASDAQ: HURA) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $1.93 (-6.31% 1D, market cap $131.3M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, HURA ranks #528 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does HURA compare to CATX and SPRB in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), HURA carries a Roarable D- (40/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CATX (Perspective Therapeutics Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $133.6M) and SPRB (Spruce Biosciences Inc.) posts a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $134.6M). Among the 5-stock peer group, HURA leads on earnings multiple (N/A) while HURA leads on capital efficiency (-35.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for HURA?
▼
Per HURA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001498382), TuHURA Biosciences Inc. generated $0 in revenue, -$31.0M in net income, and -$27.7M in free cash flow against $27.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $1.90 (-1.33%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (40/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.4% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • D-
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D+
Each axis scored 0–20
12M PRICE TARGET CONE-8.3% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for HURA)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (40/100 Composite)
🔍 WHY HURA SCORES 40/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+11/20 pts (28% of score)
20D Institutional Volume Accumulation (±12.5% realized swing band)
▲ #2 Bullish Driver: Macro Regime Fit+11/20 pts (28% of score)
FRED Regime × Technicals: 50% of 52W Range • RSI-14 at 47.5 (NEUTRAL RANGE)
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade D$1.96-10.2% Next Q
48
Q2 (-2Q)Grade D$1.76+23.9% Next Q
45
Q3 (-1Q)Grade D$2.18-11.5% Next Q
43
CurrentGrade D-$1.93-7.4% Hist 90D α
40
Trajectory: D (48) → D- (40)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a HURA Turnaround Squeeze
While HURA currently carries a cautious 40/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.02) and Max Pain ($2.03) forces dealer call-delta covering toward $3.60.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $HURA• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “HURA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why HURA Stock dropped -6.31% Today — RQD Quant Desk Flash
TuHURA Biosciences Inc. (HURA) dropped -6.31% to $1.93, trading at 50% of its 52-week range ($0.41 – $3.43). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 50% of its 52-week range ($0.41 – $3.43) with RSI-14 at 47.5 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $1.93 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live HURA Headlines & Catalysts
MARKET WIREPR Newswire • 9h ago
TuHURA Biosciences Receives New U.S. Patent Broadening Coverage for its VISTA Inhibitor, TBS-2025PR Newswire report covering TuHURA Biosciences Inc. (HURA) market action, institutional positioning, and fundamental catalysts.
MARKET WIREwww.marketscreener.com • 12h ago
TuHURA Biosciences, Inc. Provides Initial Data From Open-Label Study Of IFx-2.0 As Adjunctive Therapy To Keytruda In First-Line Treatment Of Metastatic Merkel Cell Carcinomawww.marketscreener.com report covering TuHURA Biosciences Inc. (HURA) market action, institutional positioning, and fundamental catalysts.
MARKET WIREPR Newswire • 15h ago
TuHURA Biosciences Receives Key U.S. Patent for its Groundbreaking Delta Opioid Receptor (DOR) Antibody Drug Conjugate (ADC) TechnologyPR Newswire report covering TuHURA Biosciences Inc. (HURA) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 18h ago
TuHURA Biosciences Provides First Look at Data from its Open-Label Study of IFx-2.0 as an Adjunctive Therapy to Keytruda® in First Line Treatment of Patients with Deep Seated Metastatic Merkel Cell CarcinomaYahoo Finance report covering TuHURA Biosciences Inc. (HURA) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETraders Union • 21h ago
TuHURA Biosciences, Inc. (HURA) Earnings Date, Reports and EstimatesTraders Union report covering TuHURA Biosciences Inc. (HURA) market action, institutional positioning, and fundamental catalysts.
MARKET WIREBenzinga • 6d ago
HC Wainwright & Co. Reiterates Buy on TuHURA Biosciences, Maintains $10 Price TargetHC Wainwright & Co. analyst Robert Burns reiterates TuHURA Biosciences (NASDAQ:HURA) with a Buy and maintains $10 price target.
MARKET WIREYahoo • 7d ago
TuHURA Reports Early Responses in Deep-Seated Merkel Cell Cancer StudyTuHURA Biosciences (NASDAQ:HURA) presented preliminary results from its ongoing open-label Phase 1b study of IFx-2.0 in patients with metastatic Merkel cell carcinoma, or MCC, reporting confirmed partial responses in the
MARKET WIREBenzinga • 7d ago
TuHURA Reports Initial Data Showing Partial Responses In First Three Metastatic Merkel Cell Carcinoma Patients Treated With Ifx-2.0 Plus KeytrudaPreliminary results demonstrate major objective tumor responses in first 3 patients at 6 months Company to host a webcast today, October 26, 2026, at 8:30 am ETTAMPA, Fla., Oct. 26, 2026 /PRNewswire/ -- TuHURA
MARKET WIREBenzinga • 20d ago
12 Health Care Stocks Moving In Tuesday's After-Market SessionGainers Alaunos Therapeutics (NASDAQ:TCRT) shares rose 20.5% to $3.65 during Tuesday's after-market session. The market value of their outstanding shares is at $2.6 million. Circle8 Group (NASDAQ:CIRC) stock moved
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring HURA)
- ✓Walkthrough of HURA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
HURA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -13.84%▼ DESCENDING CHANNEL
2026-10-30O $2.05H $2.05L $1.85C $1.93VOL 519.5K
RES: $2.20SUP: $1.62SMA50: $2.02SMA200: $1.97
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
HURA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on HURA today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for HURA. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for HURA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (HURA)
Health Care Rank #528 of 1016
⚔️ CATX vs HURA Full Matrix →
1. Head-to-Head Health Care Peer Comparison (HURA vs. CATX, SPRB, BGM, OGI)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, TuHURA Biosciences Inc. (HURA) ranks #528 by composite RQD confidence (40/100, grade D-) and #627 by equity capitalization ($131.3M). Within this direct 5-issuer industry benchmark cohort, HURA leads on earnings valuation at N/A trailing P/E, while HURA leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. OGI currently holds the highest overall quantitative score in the immediate peer group at 62/100 (C) compared with HURA at 40/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| HURA
ACTIVE
TuHURA Biosciences Inc. | D- | 40/100 | — | — | -35.0% | -6.31% | $131.3M | Benchmark Subject |
| CATX Perspective Therapeutics Inc. | D- | 37/100 | — | — | -35.0% | -1.71% | $133.6M | /catx-vs-hura → |
| SPRB Spruce Biosciences Inc. | D- | 42/100 | — | — | -35.0% | -0.92% | $134.6M | /sprb-vs-hura → |
| BGM BGM Group Ltd. (Class A) | D- | 35/100 | — | 16.6% | — | 0.00% | $127.4M | /bgm-vs-hura → |
| OGI Organigram Global Inc. | C | 62/100 | — | — | — | -2.85% | $135.4M | /ogi-vs-hura → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001498382In its most recent audited fiscal period (FY2025, filed 2025-12-31), TuHURA Biosciences Inc. (HURA) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$31.0M, operating cash flow of -$27.6M, and free cash flow of -$27.7M (-87.4% YoY). On the balance sheet, HURA closed FY2025 with $27.4M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$31.0M | -$27.6M | -$27.7M | $27.4M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$23.0M | -$14.7M | -$14.8M | $20.0M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$15.0M | -$12.0M | -$12.0M | — | — |
3. HURA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs HURA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, TuHURA Biosciences Inc. (NASDAQ: HURA) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $1.93 (-6.31% 1D, market cap $131.3M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, HURA ranks #528 in composite RQD confidence.
How does HURA compare to CATX and SPRB in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), HURA carries a Roarable D- (40/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CATX (Perspective Therapeutics Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $133.6M) and SPRB (Spruce Biosciences Inc.) posts a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $134.6M). Among the 5-stock peer group, HURA leads on earnings multiple (N/A) while HURA leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for HURA?
Per HURA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001498382), TuHURA Biosciences Inc. generated $0 in revenue, -$31.0M in net income, and -$27.7M in free cash flow against $27.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is HURA trading relative to its 50-day, 200-day, and 52-week technical levels?
HURA last traded at $1.93 (-6.31% on volume of 524,097 shares), positioning the stock -4.46% below its 50-day simple moving average ($2.02) and -2.03% below its 200-day simple moving average ($1.97). Across its 52-week range of $0.41 to $3.43, HURA sits at the 50.3% percentile with a 14-day RSI of 47.5 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.69 to $2.17).
HURA Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is HURA stock moving today?
Why HURA Stock dropped -6.31% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
ROARABLE RATING BRIEF • RQD 40/100 (D-)
✓ STAGE-C NUMBER FIREWALL VERIFIED
HURA — TuHURA Biosciences Inc.: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:43:04Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, HURA scores 40 out of 100 with a letter grade of D-, labeled "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are:
- Fundamental Cash Engine: 5 / 20. Per the Roarable RQD rating, this reflects ROIC of -35% and an FCF yield of -21.1%. For a prospective investor, this means the business is currently consuming cash relative to its capital base; the upside case must rest on future events rather than present cash generation.
- Whale 13F Flow: 11 / 20. Per the Roarable RQD rating, this pillar captures institutional accumulation and options positioning. Its mid-range score suggests institutional interest is present but not decisive.
- Insider Conviction: 3 / 20. Per the Roarable RQD rating, this pillar reflects SEC Form 4 and Congressional PTR cluster flow. The low score indicates weak insider signaling, which a prospective investor should weigh as a lack of visible insider confidence.
- Macro Regime Fit: 11 / 20. Per the Roarable RQD rating, this reflects a beta of 1.0 and sector sensitivity. The stock moves in line with the broader market, offering no defensive cushion.
- Forensic Balance Sheet: 10 / 20. Per the Roarable RQD rating, this reflects an Altman Z-Score of 2.5, a Piotroski F-Score of 1/9, and Debt/Equity of 0.5. The weak Piotroski reading points to deteriorating financial quality.
Taken together, the rating signals elevated fundamental and balance-sheet risk. Valuation tradeoffs are difficult to assess because earnings-based multiples are unavailable. A prospective investor evaluating the stock today would need to focus on whether the company's pipeline catalysts can justify continued cash burn before the balance sheet tightens further.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 (filed 2025-12-31) | $0.0M | $0.0M | $-31.0M | N/A | $-27.7M | $3.6M | N/A |
| FY 2024 (filed 2024-12-31) | $0.0M | $0.0M | $-23.0M | N/A | $-14.8M | $12.7M | N/A |
| FY 2023 (filed 2023-12-31) | $0.0M | $0.0M | $-15.0M | N/A | $-12.0M | N/A | N/A |
Per the SEC financials, the company reported no revenue or operating income across the three periods, with net losses widening from $-15.0M in FY 2023 to $-31.0M in FY 2025. Gross, operating, and net margins are each 0% per the market data, and ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 1/9. Reported cash declined from $12.7M to $3.6M between FY 2024 and FY 2025, and FCF was $-27.7M in FY 2025, which signals a limited liquidity runway.
Recent Catalysts & News Wire Analysis
Per the recent news feed, the catalysts are patent and clinical-data announcements:
- A new U.S. patent broadening coverage for the VISTA inhibitor TBS-2025.
- A key U.S. patent for the Delta Opioid Receptor antibody drug conjugate technology.
- Initial data from an open-label study of IFx-2.0 with Keytruda in first-line metastatic Merkel cell carcinoma.
- An earnings date and estimates item.
All items are tagged YELLOW with the impact label "MARKET WIRE." Per the Butterfly Supply-Chain Graph, the supply chain is NONE, there are no butterfly links, and there are no proprietary signals. Risk watch items include the cash decline and negative FCF noted in the financial data, and a short-term price move of -6.31% per the market data.
Open Questions
- What is the company's cash runway given the decline from $12.7M to $3.6M and FY 2025 FCF of $-27.7M?
- What is the debt balance, since debt is reported as N/A in every period?
- What outcomes or timelines are associated with the IFx-2.0 Merkel cell carcinoma study and the patent-protected programs?
- Why do the insider and institutional pillars score as they do, and what specific Form 4 or 13F transactions drove those scores?
- What is the company's revenue model, given that reported revenue is $0.0M in every period?
HURA Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for TuHURA Biosciences Inc. (HURA) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo Finance UK • 6h ago
TuHURA Biosciences, Inc. (HURA) Seasonal returns chart Yahoo Finance UK report covering TuHURA Biosciences Inc. (HURA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE PR Newswire • 9h ago
TuHURA Biosciences Receives New U.S. Patent Broadening Coverage for its VISTA Inhibitor, TBS-2025 PR Newswire report covering TuHURA Biosciences Inc. (HURA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE www.marketscreener.com • 12h ago
TuHURA Biosciences, Inc. Provides Initial Data From Open-Label Study Of IFx-2.0 As Adjunctive Therapy To Keytruda In First-Line Treatment Of Metastatic Merkel Cell Carcinoma www.marketscreener.com report covering TuHURA Biosciences Inc. (HURA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE PR Newswire • 15h ago
TuHURA Biosciences Receives Key U.S. Patent for its Groundbreaking Delta Opioid Receptor (DOR) Antibody Drug Conjugate (ADC) Technology PR Newswire report covering TuHURA Biosciences Inc. (HURA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 18h ago
TuHURA Biosciences Provides First Look at Data from its Open-Label Study of IFx-2.0 as an Adjunctive Therapy to Keytruda® in First Line Treatment of Patients with Deep Seated Metastatic Merkel Cell Carcinoma Yahoo Finance report covering TuHURA Biosciences Inc. (HURA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Traders Union • 21h ago
TuHURA Biosciences, Inc. (HURA) Earnings Date, Reports and Estimates Traders Union report covering TuHURA Biosciences Inc. (HURA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Benzinga • 6d ago
HC Wainwright & Co. Reiterates Buy on TuHURA Biosciences, Maintains $10 Price Target HC Wainwright & Co. analyst Robert Burns reiterates TuHURA Biosciences (NASDAQ:HURA) with a Buy and maintains $10 price target.
🟡 MARKET WIRE Yahoo • 7d ago
TuHURA Reports Early Responses in Deep-Seated Merkel Cell Cancer Study TuHURA Biosciences (NASDAQ:HURA) presented preliminary results from its ongoing open-label Phase 1b study of IFx-2.0 in patients with metastatic Merkel cell carcinoma, or MCC, reporting confirmed partial responses in the
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
HURA Bull vs. Bear Conversation Board — What's Your Call at $1.93?
🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON HURA 🐻 67% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH
🎯 Target: $1.81 (-12.1%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is HURA (D- • RQD 40/100) a Buy at $2.06?
Welcome to the HURA (TuHURA Biosciences Inc.) Roar Pit. Current RQD Composite is 40/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
MU MultipleCompression Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $1.65 (-19.9%)
Spot @ $2.06 Pump the brakes on HURA — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on HURA, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless TuHURA Biosciences Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
QU QuantViper Verified K Arena Trader 🐂 BULLISH
🎯 Target: $2.53 (+22.8%)
Spot @ $2.06 HURA cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on HURA, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $2.06 (52-wk range $1.78 - $2.23), any beat on forward guidance forces shorts and underweight funds to chase.